Portola Pharmaceuticals Inc. (PTLA)

25.89
NASDAQ : Health Technology
Prev Close 25.68
Day Low/High 25.26 / 26.14
52 Wk Low/High 14.81 / 42.17
Avg Volume 983.30K
Exchange NASDAQ
Shares Outstanding 68.11M
Market Cap 1.75B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
How to Play It When the FDA Slams Your Stock

How to Play It When the FDA Slams Your Stock

Here are three recent examples of how the patient can profit.

Portola Pharmaceuticals Announces Presentation Of Interim Results From Phase 3b/4 ANNEXA™-4 Study Of AndexXa™ (andexanet Alfa) At European Society Of Cardiology 2016 Congress

Portola Pharmaceuticals Announces Presentation Of Interim Results From Phase 3b/4 ANNEXA™-4 Study Of AndexXa™ (andexanet Alfa) At European Society Of Cardiology 2016 Congress

Company to Host Webcast of Investor Event with Drs. Stuart J. Connolly and C. Michael Gibson to Discuss Data on Tuesday, August 30

October 21st Options Now Available For Portola Pharmaceuticals (PTLA)

October 21st Options Now Available For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options become available today, for the October 21st expiration.

Portola Pharmaceuticals (PTLA) Stock Falls, Citi Downgrades

Portola Pharmaceuticals (PTLA) Stock Falls, Citi Downgrades

Citi lowered Portola Pharmaceuticals' (PTLA) stock rating to 'neutal' this morning.

Portola Pharmaceuticals (PTLA) Stock Slumps on FDA Complete Response Letter

Portola Pharmaceuticals (PTLA) Stock Slumps on FDA Complete Response Letter

The FDA asked Portola Pharmaceuticals (PTLA) to provide more information on a new anticoagulation reversal drug.

Strong On High Volume: Portola Pharmaceuticals (PTLA)

Strong On High Volume: Portola Pharmaceuticals (PTLA)

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a strong on high relative volume candidate

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

4 Possible Acquisition Targets in Biotech

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock

Portola Pharmaceuticals (PTLA) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "perilous reversal" (up big yesterday but down big today) candidate

Monsanto, Amazon and Apple: Doug Kass' Views

Monsanto, Amazon and Apple: Doug Kass' Views

Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.

Portola Pharmaceuticals Becomes Oversold (PTLA)

Portola Pharmaceuticals Becomes Oversold (PTLA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

Perilous Reversal Stock: Portola Pharmaceuticals (PTLA)

Perilous Reversal Stock: Portola Pharmaceuticals (PTLA)

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "perilous reversal" (up big yesterday but down big today) candidate

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo To Develop Andexanet Alfa With Edoxaban In Japan

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo To Develop Andexanet Alfa With Edoxaban In Japan

Development and Commercialization of Andexanet Alfa In Japan Fully Supported by Collaboration Partners

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says

Portola Pharmaceuticals (PTLA) Is Today's Dead Cat Bounce Stock

Portola Pharmaceuticals (PTLA) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Portola Pharmaceuticals (PTLA) as a "dead cat bounce" (down big yesterday but up big today) candidate

TheStreet Quant Rating: D- (Sell)